Shield To Buy Echodyne For $5.3 Billion And Raise $2.5 Billion At $28.8 Billion Valuation

Shield, a defense technology company developing autonomous systems and mission-critical software, has entered into a definitive agreement to acquire radar manufacturer Echodyne in a transaction valued at $5.3 billion. The company also announced plans to raise $2.5 billion through equity and debt financing, including a $1 billion Series H round at a $28.8 billion post-money valuation.

The acquisition will expand Shield’s Mission Systems business into the rapidly growing radar and counter-drone markets, combining Echodyne’s sensing technologies with Shield’s existing autonomy software, autonomous aircraft, and simulation capabilities.

The $5.3 billion transaction includes $4.8 billion in consideration payable or issuable at closing and up to $500 million in additional payments contingent on Echodyne achieving agreed performance targets.

Shield’s $2.5 billion financing package consists of a $1 billion Series H equity round, a $1 billion structured equity investment from funds managed by Blackstone, and $500 million in debt financing led by JPMorgan Chase Bank as sole arranger.

The Series H financing is co-led by Disruptive and Innovation X Capital, with participation from Advent, the Strategic Investment Group of JPMorganChase’s Security and Resiliency Initiative, Snowpoint Ventures, Apandion, Center15 Capital, and other investors. Proceeds from the Series H will be used primarily to fund the acquisition.

Both Shield and Echodyne expect triple-digit revenue growth during the current fiscal year, reflecting increasing demand for autonomous defense systems, radar technology, and counter-unmanned aircraft capabilities.

Founded in Kirkland, Washington, Echodyne develops compact, solid-state radar systems using its patented Metamaterials Electronically Scanned Array (MESA) technology. Its products are integrated into hundreds of counter-drone and security systems used by defense, government, and commercial customers in more than 40 countries.

The technology enables operators to detect and track unmanned aircraft, monitor sensitive infrastructure, secure borders, and improve situational awareness in complex operating environments.

Echodyne’s radar systems are also integrated with remote weapon stations, high-energy lasers, high-power microwave systems, and interceptor technologies, providing targeting information that supports counter-drone operations.

In September 2026, Echodyne received a contract with a $250 million ceiling from Joint Interagency Task Force 401 to provide counter-drone radar systems to U.S. and allied forces.

Beyond military applications, Echodyne’s products support security operations at airports, stadiums, and other public facilities. The company’s radar technology also helps police and fire departments operate unmanned aircraft safely in shared airspace.

The acquisition will complement Shield’s existing portfolio, which includes Hivemind autonomy software, Aechelon simulation technology for training and testing, and its V-BAT and X-BAT autonomous systems.

Shield’s strategy centers on developing three interconnected businesses: autonomy software, autonomous systems, and mission systems. Integrating Echodyne’s radar technology is expected to strengthen the company’s ability to provide coordinated sensing, decision-making, and autonomous operations.

Following completion, Echodyne will continue operating its radar business and supplying systems to existing integrators and customers. Its MESA radar products will remain available as standalone offerings.

Echodyne CEO Eben Frankenberg will report directly to Shield CEO Gary Steele and retain responsibility for the company’s products, manufacturing operations, customer relationships, and industry partnerships.

The transaction will also expand Shield’s manufacturing presence in Washington state.

Echodyne recently opened an 86,350-square-foot manufacturing facility representing a $40 million investment. The facility is designed to support annual production of approximately 30,000 radar systems.

Shield separately selected Washington as the production location for its X-BAT autonomous aircraft in September 2026, adding another manufacturing initiative in the region.

The acquisition is expected to close in early 2027, subject to regulatory approvals and customary closing conditions.

J.P. Morgan Securities served as exclusive financial adviser to Shield on the acquisition, while Wachtell, Lipton, Rosen & Katz acted as legal adviser. Covington & Burling advised on regulatory and business diligence matters, and Sullivan & Cromwell served as legal adviser on the financing.

Morgan Stanley and Robert W. Baird served as financial advisers to Echodyne, while Fenwick & West acted as its legal adviser.

The transaction represents a major expansion of Shield’s defense technology platform, combining advanced radar sensing with autonomous systems and software while increasing its exposure to military and commercial counter-drone markets.

KEY QUOTES

“We are building a new-generation defense technology company consisting of three fast-growing, high-margin, mutually supporting business units: autonomy software, autonomous systems, and mission systems. The acquisition of Echodyne dramatically accelerates our efforts to meet growing customer demand for multi-mission capabilities, provides increased access to a rapidly expanding counter-drone industry, and further diversifies our revenue streams with sustained, compelling growth for the combined company.”

Gary Steele, CEO Of Shield

“Hundreds of customers rely on our radars to detect and track drones, protect people and infrastructure, secure borders, and ensure safe airspace operations. Shield shares our view that autonomous systems can only act on what they can sense, and superior sensors lead to superior systems and outcomes. By joining Shield, we’re creating a company with the size and breadth to deliver even more value to our broad range of defense, government, and commercial customers around the globe.”

Eben Frankenberg, CEO of Echodyne